# Hepatic Cirrhosis

Cirrhosis may remain clinically silent despite normal routine liver tests. Recognize portal-hypertension signals, stage fibrosis noninvasively when appropriate, identify decompensation promptly, treat the underlying etiology, and refer early for complication-directed and transplant-centered care.

**Clinical question:** How should clinicians identify cirrhosis, recognize decompensation, and prioritize management of major complications?

Updated: 2026-08-21T00:40:46.470834+00:00

## What matters in practice
- Normal aminotransferases, alkaline phosphatase, and bilirubin do not exclude cirrhosis; thrombocytopenia should prompt evaluation for chronic liver disease and cirrhosis. [9]
- Decompensation is marked clinically by complications such as ascites, hepatic encephalopathy, or variceal bleeding and is associated with hospitalization and poor short-term prognosis. [9]
- Liver biopsy with histologic assessment remains the reference standard for diagnosing and staging steatohepatitis and fibrosis when that distinction is required. [1]
- Ascites is a major prognostic transition: approximately 20% of patients with cirrhosis have ascites at presentation, and approximately 20% presenting with ascites die within 1 year. [2]
- For selected patients with ascites or hepatic hydrothorax, TIPS requires careful risk assessment; caution is advised with age older than 70 years, bilirubin above 50 µmol/L, platelets below 75 × 10^9/L, MELD score 18 or greater, current encephalopathy, active infection, or hepatorenal syndrome. [2]

## When to suspect cirrhosis despite nondiagnostic routine testing

Compensated disease is often clinically inapparent.

Cirrhosis has a compensated phase in which patients may feel well and a decompensated phase defined by onset of complications, including ascites, hepatic encephalopathy, and variceal bleeding. Routine liver enzyme, alkaline phosphatase, and bilirubin values can be normal in cirrhosis; do not use normal results to dismiss concern raised by thrombocytopenia or other clinical evidence of chronic liver disease. [9]

The immediate clinical task is not simply to label cirrhosis, but to establish the underlying etiology, estimate fibrosis and portal-hypertension burden, and determine whether prior or current decompensation has occurred. Etiologic therapy should be initiated as early as possible at any stage of hepatic disease. [8]
- Treat thrombocytopenia as a clinical signal warranting assessment for chronic liver disease and cirrhosis. [9]
- Ask specifically about ascites, overt or subtle cognitive change consistent with hepatic encephalopathy, and prior gastrointestinal bleeding, because these events reclassify disease as decompensated. [9]
- Assess for bacterial infection, acute kidney injury, hepatorenal syndrome, and hepatocellular carcinoma because these may accelerate the course of cirrhosis, particularly after decompensation. [8]

*Clinical phase and immediate implication in cirrhosis. [8][9]*

| Clinical state | Defining features | Management implication |
| --- | --- | --- |
| Compensated cirrhosis | May be asymptomatic; routine liver enzymes and bilirubin can be normal. [9] | Confirm chronic liver disease severity, determine etiology, and institute etiologic treatment early. [8][9] |
| Decompensated cirrhosis | Ascites, hepatic encephalopathy, and/or variceal bleeding indicate decompensation. [9] | Evaluate the complication and potential precipitants promptly; bacterial infection and acute kidney injury may worsen the course. [8][9] |

## Use fibrosis assessment to answer a defined clinical question

No single approach answers every diagnostic and prognostic question.

In metabolic dysfunction-associated steatotic liver disease terminology used in older source materials as NAFLD/NASH, clinical and routine laboratory testing cannot reliably distinguish nonalcoholic fatty liver from steatohepatitis. Liver biopsy with histologic assessment is the reference standard when diagnosis and staging of steatohepatitis or fibrosis are necessary. [1]

Noninvasive blood- and imaging-based fibrosis tests can support risk stratification, but their predictive performance is context dependent. Patented and nonpatented fibrosis markers predict decompensation largely through association with advanced fibrosis; their prognostic performance declines once cirrhosis is already established. [12]

Enhanced Liver Fibrosis testing has shown prognostic association in mixed liver-disease populations, including an AUC of 0.87 for 6-year prediction of decompensation and liver-related death; however, among patients with established cirrhosis, reported discrimination for liver-related events was lower. [12] Use such tests as adjuncts to—not replacements for—clinical assessment of decompensation and complication risk.
- Use noninvasive testing to estimate advanced fibrosis risk and guide referral or further evaluation, recognizing that accuracy varies by etiology and disease spectrum. [12]
- Consider biopsy when histologic distinction between steatosis and steatohepatitis, or precise fibrosis staging, will alter management or eligibility decisions. [1]
- Do not equate a fibrosis biomarker result with absence of clinically meaningful portal-hypertension complications in a patient with established cirrhosis. [12]

*Interpretive limits of selected fibrosis-assessment approaches. [1][12]*

| Approach | Best-supported use in supplied evidence | Important limitation |
| --- | --- | --- |
| Liver biopsy with histology | Reference standard for diagnosis and staging of steatohepatitis and fibrosis. [1] | Invasive; the supplied evidence does not provide a universal biopsy threshold. [1] |
| Noninvasive fibrosis markers | Risk stratification through correlation with advanced fibrosis and prediction of subsequent decompensation. [12] | Performance is strongest across a broad fibrosis spectrum and declines in established cirrhosis. [12] |
| ELF test | Reported AUC 0.87 for 6-year prediction of decompensation and liver-related death in a mixed population. [12] | Reported prognostic discrimination is lower after cirrhosis has been diagnosed. [12] |

## Treat ascites as a high-risk prognostic event

Ascites signals a major change in the clinical course.

Ascites reflects portal hypertension together with renal sodium and water retention. It is a major landmark in cirrhosis: about 20% of patients with cirrhosis have ascites at first presentation, and about 20% of those presenting with ascites die during the first year after diagnosis. [2]

Hyponatremia is categorized as mild at serum sodium 130–135 mmol/L, moderate at 125–129 mmol/L, and severe below 125 mmol/L. [2] In a patient with ascites, serial sodium and renal assessment is clinically important because kidney dysfunction, hepatorenal syndrome, and infection are consequential complications of decompensated disease. [2][8]
- Recognize new ascites as a transition requiring reassessment of disease severity and complications. [2]
- Classify serum sodium below 135 mmol/L as hyponatremia; values below 125 mmol/L are severe. [2]
- Escalate evaluation when ascites coexists with infection, acute kidney injury, hepatorenal syndrome, or encephalopathy, which are high-risk features in decompensated cirrhosis. [2][8]

*Serum sodium categories cited in ascites guidance. [2]*

| Serum sodium | Category |
| --- | --- |
| 130–135 mmol/L | Mild hyponatremia. [2] |
| 125–129 mmol/L | Moderate hyponatremia. [2] |
| <125 mmol/L | Severe hyponatremia. [2] |

## Prioritize etiologic treatment and complication-directed referral

Management depends on the cause and the specific decompensating event.

The supplied evidence supports early etiologic treatment across stages of chronic liver disease and emphasizes prompt identification and management of cirrhosis complications. [8][9] For chronic hepatitis C, direct-acting antiviral treatment prevents progression of HCV-related liver disease and reduces risk of cirrhosis, decompensation, and hepatocellular carcinoma; patients with advanced fibrosis or cirrhosis require linkage to ongoing surveillance for HCV-related complications. [24]

The available sources do not provide sufficient support for a universal U.S. medication regimen, diuretic dosing protocol, paracentesis protocol, variceal prophylaxis regimen, or hepatocellular carcinoma surveillance interval. These decisions should therefore be verified against current disease-specific U.S. guidance and individualized to renal function, sodium concentration, hemodynamics, encephalopathy, infection status, and transplant candidacy.

### TIPS selection

TIPS should be considered for hepatic hydrothorax after multidisciplinary discussion. [2] In patients being considered for TIPS, caution is advised with age older than 70 years, bilirubin greater than 50 µmol/L, platelet count below 75 × 10^9/L, MELD score 18 or greater, current hepatic encephalopathy, active infection, or hepatorenal syndrome. [2]
- Use multidisciplinary review for TIPS candidacy, particularly when encephalopathy, infection, renal dysfunction, or adverse prognostic markers are present. [2]
- Discuss suitability and timing of umbilical hernia repair with the patient and a multidisciplinary team involving physicians, surgeons, and anesthetists. [2]

### Medication safety

Hepatic impairment can alter drug pharmacokinetics, and cirrhosis may reduce tolerance of drug-induced hepatotoxicity. [6][18] The supplied evidence does not support drug-specific dose adjustments for general cirrhosis management; use current FDA labeling and agent-specific hepatic-impairment recommendations rather than applying a generic dose-reduction rule.
- Reassess drug necessity, interaction potential, and hepatic- and renal-impairment labeling whenever decompensation or acute kidney injury occurs. [6][18]

*Situations requiring specialty-centered management or multidisciplinary discussion. [2][8][24]*

| Clinical scenario | Decision focus |
| --- | --- |
| Advanced fibrosis or cirrhosis with chronic HCV | Provide antiviral treatment and linkage to surveillance for HCV-related complications. [24] |
| Hepatic hydrothorax | Consider TIPS after multidisciplinary discussion. [2] |
| Potential TIPS candidate with MELD ≥18, active encephalopathy, infection, hepatorenal syndrome, bilirubin >50 µmol/L, platelets <75 × 10^9/L, or age >70 years | Proceed with caution because these are adverse selection features identified in ascites guidance. [2] |
| Umbilical hernia in cirrhosis | Plan timing and suitability through physician, surgeon, anesthetist, and patient discussion. [2] |

## A focused clinical workflow

Avoid reliance on a single laboratory value or fibrosis test.

For suspected cirrhosis, first establish whether the patient is compensated or has experienced ascites, encephalopathy, or variceal bleeding. Concurrently evaluate the cause of liver disease and assess fibrosis using noninvasive tools or biopsy when histology will change management. [1][8][9][12]

For decompensated disease, identify the active complication and assess for infection, acute kidney injury, hepatorenal syndrome, sodium abnormalities, and hepatocellular carcinoma, all of which can influence the clinical trajectory. [2][8] Refer early to hepatology and involve multidisciplinary teams for complex procedural decisions, including TIPS and abdominal wall hernia repair. [2]
- Do not exclude cirrhosis because liver enzymes or bilirubin are normal. [9]
- Document prior decompensating events even if the patient currently appears compensated. [9]
- Use fibrosis tests as risk tools, not as stand-alone substitutes for clinical staging in known cirrhosis. [12]
- Treat the etiology early and maintain surveillance linkage in advanced fibrosis or cirrhosis, including after HCV cure. [8][24]

*High-yield sequence for suspected or established cirrhosis. [1][2][8][9][12][24]*

| Step | Action |
| --- | --- |
| 1. Recognize | Investigate thrombocytopenia and other signals of chronic liver disease even when routine liver tests are normal. [9] |
| 2. Stage clinically | Determine whether ascites, encephalopathy, or variceal bleeding has occurred. [9] |
| 3. Define cause and fibrosis burden | Use noninvasive fibrosis assessment selectively; obtain biopsy when histology is needed for diagnosis or staging. [1][12] |
| 4. Address decompensation | Evaluate ascites and associated sodium, renal, infectious, and hepatorenal complications. [2][8] |
| 5. Maintain longitudinal specialty care | Treat the underlying cause early and link advanced-fibrosis or cirrhosis patients to complication surveillance. [8][24] |

## Common questions

### Can normal liver enzymes exclude cirrhosis?

No. Patients with cirrhosis may have normal liver enzymes, alkaline phosphatase, and bilirubin. Thrombocytopenia should prompt evaluation for chronic liver disease and cirrhosis. [9]

### What events define decompensated cirrhosis?

Ascites, hepatic encephalopathy, and variceal bleeding are cited clinical manifestations marking decompensation. [9]

### When is liver biopsy still useful in suspected steatohepatitis-related cirrhosis?

Biopsy with histologic assessment remains the reference standard when distinguishing steatosis from steatohepatitis or staging fibrosis is necessary for the clinical decision. [1]

### Which findings warrant caution before TIPS?

Caution is advised with age older than 70 years, bilirubin above 50 µmol/L, platelets below 75 × 10^9/L, MELD score 18 or greater, current encephalopathy, active infection, or hepatorenal syndrome. [2]

## References
1. Circulating Biomarkers for Diagnosis of Non-Alcoholic ... — www.fda.gov — https://www.fda.gov/media/135355/download
2. Guidelines on the management of ascites in cirrhosis | Gut — gut.bmj.com — https://gut.bmj.com/content/70/1/9
3. JAMA Network | Home of JAMA and the Specialty Journals of the American Medical Association — jamanetwork.com — https://jamanetwork.com
4. Development of a Simple Machine Learning Model to ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772522
5. Performance of the Enhanced Liver Fibrosis Test to ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784186
6. Dose recommendations for anticancer drugs in patients ... — www.thelancet.com — https://www.thelancet.com/article/S1470204519301457/pdf
7. Hepatitis C — go.nature.com — https://go.nature.com/3Fs35UK
8. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0168827818319664
9. Key Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its Complications — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0002934324003267
10. Understanding the Complexities of Cirrhosis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0149291815008462
11. Compensated Liver Cirrhosis - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/compensated-liver-cirrhosis
12. Noninvasive assessment of hepatic decompensation : Hepatology — journals.lww.com — https://journals.lww.com/hep/fulltext/2025/03000/noninvasive_assessment_of_hepatic_decompensation.27.aspx
13. Simple way to use non-invasive tests for... : Hepatology — journals.lww.com — https://journals.lww.com/hep/fulltext/01515467-201310001-01464~simple-way-to-use-non-invasive-tests-for-cirrhosis-diagnosis
14. Medicine® — journals.lww.com — https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-201703030-00004
15. S3255 Frequency of Cirrhosis Diagnostic... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0000715068.87190.c7~s3255frequency-of-cirrhosis-diagnostic-disagreement-between
16. Pediatric Hepatic Impairment Dosing in FDA Approvals ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.70011
17. Re‐discover the value of protein binding assessments in ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13810
18. Prescribing Medications in Patients with Decompensated Liver ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.4061/2011/519526
19. ACCP Abstract Booklet - 2022 - Wiley Online Library — accp1.onlinelibrary.wiley.com — https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.1151
20. discover the value of protein binding assessments in hepatic ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13810
21. New Insights Into Hepatic Impairment (HI) Trials — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.70130
22. Physiologically Based Pharmacokinetic Modeling of ... — accp1.onlinelibrary.wiley.com — https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.70164
23. The Viloxazine Paradox: A Noradrenergic Agent's Journey ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/cns.70839
24. AASLD/IDSA 2023 Clinical Practice Guidance Update for Testing, Managing, and Treating Hepatitis C Virus Infection — www.idsociety.org — https://www.idsociety.org/practice-guideline/hcv-guidance

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.